386 results about "Liver Cirrhoses" patented technology

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and / or to develop and monitor the outcome of therapeutic treatments. An exemplary disease / condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.

Fibrosis arises as part of a wound healing response that maintains organ integrity following catastrophic tissue damage, but can also contribute to a variety of human pathologies, including liver cirrhosis. The invention demonstrates that cellular senescence acts to limit the fibrogenic response to tissue damage, thereby establishing a role for the senescence program in pathophysiological settings beyond cancer. Accordingly, the methods of the invention relate to modulating cellular senescence in disease tissue that have elevated numbers of senescent cells, such as in fibrotic tissues.

The invention relates to a method for establishing a Gadd45a knockout rabbit model by adopting a knockout technology and belongs to the technical field of biotechnology. The invention aims to establish a rabbit model by knocking out GADD45a gene by utilizing a Grispr / cas9 technology and to provide the method for establishing the Gadd45a knockout rabbit model by adopting the knockout technology andfor researching the influence of the gene on animal liver. The method provided by the invention comprises the following steps: establishing sgRNA; synthesizing double-stranded DNA; linearizing p UC-57 carrier; linking p UC-57 carrier with double-stranded DNA; converting; performing monoclonal picking and plasmid DNA extraction; identifying plasmid sequence; expressing plasmid with CAS9; and performing digestion linearization for in vitro transcription. Through related detection, the invention successfully acquires the Gadd45a knockout rabbit model; the model is established for simulating theclinic pathological processes of the liver diseases, such as, fatty liver, liver cirrhosis and liver cancer after giving the corresponding alcohol stimulation, is capable of effectively forecasting the clinic application effects of new vaccine, new drugs and new diagnostic reagents, and meanwhile, and is capable of greatly reducing the risk in researching and developing the new drugs; and a basismodel is supplied for the clinical research.

The invention provides a product having sobering up and liver protecting functions and its preparation method and use, which comprises the following raw material (by weight ratio), soybean peptides and soybean extract 2.5-12:0.5, panaxoside or ginkgo leaf extract, green tea polyphenols, glutacid, arginine or lycine, vitamin C, vitamin B6, vitamin B1, vitamin B2 or vitamin B12. The medicament can be made into various dose forms including capsule, oral liquid, tablet, effervescent tablet or injection.

Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and / or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

Disclosed is a method for diagnosing whether a subject suffers from a mild or severe form of liver cirrhosis based on determining the amount of GDF-15 (growth differentiation factor 15), PlGF (placental growth factor), and / or hepatocyte growth factor (HGF) in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts). The method may further include determining the amount of adiponectin in a sample from the subject, and comparing the amount to a reference amount for adiponectin. Also described is a method to identifying a subject being susceptible to liver transplantation including determining the amount of GDF-15, PlGF, and / or HGF in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts).

The present invention provides heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein.The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The invention is directed to tricyclic benzodiazepines useful as vasopressin receptor antagonists for treating conditions involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising tricyclic benzodiazepines of the present invention and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.

The invention provides a traditional Chinese medicine composition resistant to liver cancer, made by adopting oldenlandia diffusa, selfheal, herba solani nigri, garden balsam stem, polygonum cuspidatum, sculellaria barbata, rhizoma sparganii, curcuma zedoary, airpotato yam rhizome, cowherb seed, pariphyllin, ligusticum chuanxiong hort, oriental wormwood, oriental waterplantain rhizome, costus root, grifola, poria, radix curcumae, radix bupleuri, rheum officinate, fructus aurantii, centipede, scorpio, borneol, yellow lead and storax as raw materials. The invention also discloses medicine coat made by the composition, the medicine coat is made by the process of socking, decocting, socking again, decocting again and drying in the shade. The medicine coat resistant to liver cancer of the invention not only is resistant to liver caner but also has the function of treating liver cirrhosis and cleaning liver virus, has the effects of cancer prevention, cancer resistance, apocatastasis dissipate blood stasis, inhibiting cancer cell diffusion and improving liver micro circulation, has no toxic or side effect and is effective in control and curative effect on early and mid-term liver cancer.

The invention discloses a traditional Chinese medicine composition for treating liver cirrhosis and fibrosis and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared by the bulk drugs of radix salviae miltiorrhizae, black soya bean, red paeony root, ophiopogon root, astragalus root, radix codonopsis pilosulae, angelica, carapax amydae, rhizoma zedoariae, twotooth achyranthes root, Chinese yam, giant knotweed, hedyotis diffusa, fructus amomi and honey-fried licorice root. The prescription disclosed by the invention is complete in the matching of a monarch, a minister, an adjuvant and a conductant drug, is excellent in the efficacy of drugs, is flexible in application and has the comparatively obvious characteristic of traditional Chinese medicine. The traditional Chinese medicine composition disclosed by the invention has the actions of resisting the fibrosis, resisting hepatitis B virus (HBV) replication, improving the liver function, regulating the blood circulation of the liver, reinforcing the liver, softening hard masses, strengthening the spleen and the like; and the traditional Chinese medicine composition also has the actions of lowering the portal pressure, reducing the thickness of the spleen and improving the liver function. The traditional Chinese medicine composition disclosed by the invention has an obvious curative effect in the therapeutic action to the liver cirrhosis and fibrosis. In addition, the traditional Chinese medicine composition disclosed by the invention has an obvious action of resisting the liver cirrhosis and fibrosis of children.

The invention relates to the field of diagnosis and treatment of liver cirrhosis and liver fibrosis, in particular to application of Golgi protein 73(GP73) and matter for detecting the concentration of the Golgi protein 73(GP73) in preparation of products for screening or auxiliarily diagnosing liver cirrhosis or liver fibrosis related diseases or products for auxiliarily judging prognosis of the diseases. It is proved that the Golgi protein 73(GP73) can serve as a novel liver cirrhosis marker, also has diagnosis value on liver cirrhosis caused by non-b hepatitis virus infection, and has no diagnosis value on primary liver cancer.

The invention relates to a drug combination of a multi-poly (ADP-ribose) polymerase (PARP) inhibitor, a method of treating or preventing HBV-related diseases by utilizing the drug combination, and the application of the drug combination. More specifically, the invention relates to a drug combination comprising 1-(ciprofloxacin formyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluoro benzoyl] piperazine, a method of treating or preventing HBV, liver cancer, liver cirrhosis and other HBV-related diseases by utilizing the drug combination, and the application of the drug combination.

The invention provides a composition containing at least one triterpene glucoside or an analogue, a metabolite, a precursor, a derivative, a medicinal active salt or a pre-drug thereof and application of the composition in preparing medicaments for treating and / or preventing viral infection. The invention also provides application of a joint composition consisting of the composition and a composition containing fluvastatin or an analogue, a metabolite, a derivative, a medicinal active salt, a precursor or a pre-drug thereof in preparing medicaments for treating and / or preventing viral infection. The composition and the method can be further used for preventing infection of subject patients or the attack and development of other disease symptoms related to viral infection of hepatitis C, such as liver cirrhosis, decompensatory liver diseases and / or hepatocellular carcinoma.

The invention provides a traditional Chinese medicine preparation for treating liver cancer, comprising the following raw medicines in parts by weight: 10-20 parts of acanthopanax, 10-20 parts of oldenlandia diffusa, 10-20 parts of radix astragali, 10-20 parts of cambogia, 10-20 parts of glossy privet fruit, 10-20 parts of white atractylodes rhizome, 10-20 parts of radix polygoni multiflori preparata, 10-20 parts of oriental wormwood, 10-20 parts of turmeric, 10-20 parts of selfheal, 10-20 parts of umbellate pore fungus, 10-20 parts of magnolia vine fruit, 10-20 parts of curcuma zedoary, 10-20 parts of tuckahoe, 10-20 parts of eclipta, 10-20 parts of root of red-rooted salvia, 10-20 parts of white peony root, 10-20 parts of barbed skullcap herb, 10-20 parts of baical skullcap root, 10-20 parts of epimedium, 1-10 parts of toad venom and 1-10 parts of scorpion. The traditional Chinese medicine preparation for treating liver cancer has the beneficial effects of prolonging the life time of inoperable patients, playing an adjuvant treating effect on patients treated mainly by operation, radiation treatment and chemo-treatment, and having certain curative effects on liver cancer-specific backgrounds of liver diseases such as hepatitis and liver cirrhosis.

The invention provides a preparation method of a conjugate in the formula (I) and application thereof as medicine preventing or treating liver cirrhosis, adiposis hepatica, hyperlipidemia, hyperglycemia, obesity and hepatic fibrosis. Pharmacological experiments find that the conjugate has drug activity with various value. Specifically, the conjugate shows the functions of reducing blood sugar and low-density lipoprotein and improving the transaminase level in animal experiments. Besides, the invention further relates to a preparation, a preparation method and application of the conjugate.

The invention relates to a glycyrrhizic acid derivative, preparation thereof and use thereof. The derivative has high water solubility and high storage stability and is suitable to be used in medicaments and health-care products for treating or preventing hepatitis, liver cirrhosis, hemorrhagic fever of liver damage and liver dysfunction syndrome, allergic purpura, psoriasis vulgaris, eczematousdermatitis and the like.

The invention provides an exosome from adipose-derived stem cells and a preparation method thereof. The exosome from the adipose-derived stem cells can be used for treating an acute hepatic failure, liver fibrosis, liver cirrhosis and other liver diseases. The exosome from the adipose-derived stem cells can remarkably increase the survival rate of a patient with the acute hepatic failure and evencan realize the 100% survival rate of the patient with the acute hepatic failure under high concentration.

The invention belongs to the technical field of medicines, and particularly relates to a JNK (stress-activated kinases,SAPK) inhibitor compound as shown in the general formula (I), pharmaceutically acceptable salts or stereoisomers thereof, preparation method of the compounds, pharmaceutical preparations containing the compounds, and use of the compounds in preparing medicines for treatment and / or prevention of ischemia reperfusion injury, diabetes, neurodegenerative diseases, chronic inflammation, pulmonary fibrosis, liver fibrosis, fatty liver and liver cirrhosis, wherein R1, R2, R3, R4 and R5 are as defined in the specification.

The invention discloses a vegetable noodle, which is prepared from the following raw materials by weight: 90-100 parts of wheat, 50-60 parts of soybeans, 30-40 parts of brown rice, 25-30 parts of Chinese chestnut, 20-30 parts of lettuce, 20-30 parts of cabbage, 25-35 parts of wax gourd, 15-20 parts of dried mushroom, 30-40 parts of a pork ribs soup, 1-2 parts of chestnut leaf, 1-3 parts of glutinous rehmannia leaf, 1-2 parts of caulis bambusae in taeniam, 1-2 parts of Rubiaceae Borreria stricta, 1-2 parts of a food additive and a proper amount of water. The noodle provided by the invention employs wheat, soya bean and brown rice as the main raw materials; the soybean has the effects of invigorating spleen, benefiting Qi, easing the middle, moisturizing dryness, nourishing blood, lowering cholesterol, alleviating water retention and resisting cancer; brown rice has the effects of strengthening the spleen and stomach, supplementing the center and boosting qi, regulating the five internal organs, calming the nervous and promoting digestion and absorption; the additional lettuce has the effects of dredging, reducing accumulation, descending qi, strengthening the body, resisting cancer, widening intestines and relaxing bowels; wax gourd has the effects of moistening lung, promoting the secretion of saliva or body fluid, reducing phlegm, quenching thirst, inducing diuresis to reduce edema, clearing away summer heat, detoxifying and expelling pus; and dried mushroom has the effects of preventing and curing cold, resisting cancer, lowering cholesterol and preventing the liver cirrhosis.

The invention discloses dendrobium anti-alcohol liver protection tea and a preparation method thereof, and the dendrobium anti-alcohol liver protection tea is composed of the following raw materials by weight: 20-30 parts of dendrobium, 80-100 parts of white tea, 16-22, parts of penthorum chinense pursh, 10-15 parts of jequirity stem, 6-12 parts of Chinese wolfberry leaf, 3-6 parts of phyllanthus urinaria, 4-8 parts of pomelo peel 6-9 parts of radix puerariae, 1-3 parts of milk thellostle, 2-5 parts of purple flower ssowthistle, 1.5-2.5 parts of chamomile, 1-2 parts of water chestnut leaf, 2-3 parts of gardenia, 0.5-1.5 parts of Melissa, 1-2 parts o spearmint, and the proper amount of water. The dendrobium anti-alcohol liver protection tea has the effects of clearing heat, detoxifying, dispelling the effects of alcohol, removing jaundice, resolving dampness, and protecting liver, can accelerate the metabolism of ethanol, reduces blood ethanol concentration, has a protective effect on the liver, can reduce the damage to the liver, can help to treat alcoholic fatty liver, alcoholic fatty liver, alcoholic liver fibrosis and alcoholic cirrhosis caused by alcohol drinking by long-term drinking, is free of side effect, and has wide application prospect and enormous economic benefits.

The invention relates to a medicine for treating liver disease, which is made from the following raw materials comprising kudzuvine root, peppermint, white hyacinth bean, sharpleaf galangal fruit, tangerine peel, amomum fruit, pseudostellaria root, trogopterus dung, red sage root and membrane of chicken gizzard. The amomum fruit, white hyacinth bean, sharpleaf galangal fruit, tangerine peel and kudzuvine root are processed into fine powder; the peppermint is soaked to obtain a supernatant; the pseudostellaria root, the trogopterus dung, the red sage root and the membrane of chicken gizzard are added with water for decoction, cooled and filtered to obtain a filtrate; the drug dregs are added with water for another decoction, then cooled and filtered to obtain another filtrate; the filtrates are combined; the fine powder, the supernatant and the filtrates are mixed, and added with ethanol for lixiviation, thus preparing a semi-finished extractum product; then the extractum product is made into capsules or tablets or medicinal granule or aqua. The medicine has important effects of expelling the toxin and protecting the liver for chemical liver injuries which include alcohol liver injury and also liver injuries caused by medical, industrial and chemical harmful substances. The medicine has obvious curative effect on a plurality of liver diseases such as alcohol liver injury, fatty liver, hepatic cirrhosis, hepatitis, etc.

The invention discloses a construction method of a decompensated liver cirrhosis combined infection risk prediction model. The method comprises the following steps: S1, data acquisition: collecting decompensated liver cirrhosis patient information; S2, data preprocessing: cleaning and sorting the original data; S3, index screening by adopting LASSO regression: dividing the patients into an infection group and a non-infection group according to whether the patients have combined infection or not, and performing single-factor analysis on the grouped index data of the patients to obtain single-factor meaningful indexes; bringing the single-factor meaningful indexes into Lasso regression for index re-screening to obtain indexes for constructing a prediction model; and S4, prediction model construction: constructing the prediction model by using the indexes screened by Lasso regression through multi-factor Logistic regression. The method is based on application of a clinical big data methodand is high in reliability; the constructed model is simple and easy to use, and the used indexes can be obtained through conventional inspection and are easy to obtain.

The invention relates to a Chinese medicinal composition for treating chronic hepatitis, splenauxe and cirrhosis. The Chinese medicinal composition consists of the following Chinese herbal medicines in part by weight: 20 to 30 parts of Chinese angelica, 15 to 25 parts of white paeony root, 20 to 40 parts of tortoise plastron, 18 to 30 parts of starfish, 30 to 60 parts of turtle shell, 12 to 24 parts of bupleurum, 15 to 30 parts of ginseng, 30 to 60 parts of astragalus, 15 to 30 parts of garden burnet root, 6 to 15 parts of zedoary, 6 to 20 parts of rhubarb and 12 to 25 parts of root of red-rooted salvia. The Chinese medicinal composition can be prepared into water pills to be taken directly, and is obvious in a curative effect and convenient to take. By clinical observation, the effectiverate is 93 percent, and the diseases do not relapse after healing.

The invention belongs to the field of traditional Chinese medicines or the pharmaceutical chemistry, and relates to a use of schisandrin B or a Chinese magnoliavine extract in the preparation of medicines for treating and / or adjunctively treating and / or preventing liver fibrosis or liver cirrhosis, medicines for treating or adjunctively treating diseases caused by the liver fibrosis or liver cirrhosis, or medicines for inhibiting liver stellate cell proliferation or DNA synthesis. The invention also relates to a method for inhibiting the liver stellate cell proliferation or inhibiting the liver stellate cell DNA synthesis in vitro / in vivo, and a medicinal composition containing the schisandrin B or the Chinese magnoliavine extract. It is proved that the schisandrin B can obviously improve the liver fibrosis or the liver cirrhosis degree, has no obvious hepatotoxicity and has a good application prospect.

The invention provides novel liver function controlling agents and others. The liver function controlling agents of the present invention are useful as preventive / therapeutic agents for diseases such as hepatic dysfunction, hepatitis, liver cancer, liver cirrhosis, etc.

The invention belongs to the technical field of clinical medical diagnosis and relates to a screening method of early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis. The screening method of the early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis liver cirrhosis and hepatitis comprises the following steps of: S1, acquiring data, specifically, collecting a target plasma sample and detecting metabolites in the plasma sample; S2, constructing a discrimination model used for distinguishing people with liver cirrhosis from patients with the primary liver cancer and distinguishing people with the hepatitis from patients with the primary liver cancer; S3, screening markers; and S4, verifying diagnosis capability. According to the screening method of early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis, a high performance liquid chromatography-mass spectrometry system is utilized to obtain the metabolic profiles of blood plasma of patients with liver cirrhosis, hepatitis and hepatocellular carcinoma, a potential tumor metabolic marker group is found, and a diagnosis model is constructed and is used for assisting early diagnosis of tumors of groups with high risk of liver cancer.

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.

This invention provides a liver cirrhosis detection kit and detection method, and belongs to the biotechnology field. According to the detection method, anti-human chitinase 3 protein 1 (CHI3L1) antibody coats a microporous plate for preparation of a solid phase antibody, when in use, a to-be-tested sample is added into the microporous plate coated with the antibody, if the to-be-tested sample contains a tested matter, the to-be-tested sample can be combined on the solid phase antibody to form an antigen-antibody complex; then a biotin-labeled anti-human CHI3L1 antibody is added to form an antibody-antigen-biotin-labeled antibody complex; horse radish peroxidase (HRP)-labeled avidin is added to form an antibody-antigen-biotin-labeled antibody-enzyme labeled avidin complex; and finally the complex is added into 3, 3 ', 5, 5 '-tetramethyl benzidine substrate system for chromogenic reaction. After the chromogenic reaction is completed, an enzyme standard instrument is used or testing. The liver cirrhosis detection kit has the advantages of fast, simple and accurate determination of test results.